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REVIEW
Abstract: Prevalence and severity of erectile dysfunction (ED) increase with aging and 
are often associated with illnesses, like diabetes mellitus, heart disease, and hypertension, 
pathologically characterized by endothelial dysfunction and whose prevalence increases with 
age. The assumption that ED is mainly a neurovascular disease is supported by the evidence 
that speciﬁ  c phosphodiesterase type 5 (PDE5) inhibition produces an efﬁ  cient erection in a 
wide range of ages and conditions. The availability of speciﬁ  c PDE5 inhibitors has enabled 
the development of effective treatment strategies, in this contest, tadalaﬁ  l may be considered 
as the least “typical” PDE5 inhibitor. In clinical trials, tadalaﬁ  l signiﬁ  cantly enhanced, in 
patients of different ages, all efﬁ  cacy outcomes across disease etiologies and severities. With 
an effectiveness lasting up to 36h, tadalaﬁ  l allows patients to choose when to have sexual 
activities without the need to time it, showing positive feedback in terms of quality of life 
related to the treatment. Headache and dyspepsia were the most frequent side-effects of 
tadalaﬁ  l, followed by back pain, nasal congestion, myalgia, and ﬂ  ushing, but the impact that 
long time action could have on effectiveness and safety is not yet entirely deﬁ  ned. The aim 
of this article is to critically review the available evidence from the tadalaﬁ  l clinical research 
program and give the physician a rational approach for intervention in the treatment of ED 
and related diseases.
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Introduction
Epidemiological studies suggest that ED is a common disorder in men, affecting 
up to 52% of men between the age of 40 and 70 years (Feldman et al 1994). 
Consistent with increasing life expectancies, the prevalence and the severity of 
ED increases in the elderly because of the aging process and related organic, 
iatrogenic and social problems (Feldman et al 1994; Parazzini et al 2000; Derby 
et al 2001; Kubin et al 2003). Meanwhile, a decline of testosterone (T) level is 
observed with age (Harman et al 2001), even though this phenomenon may be 
largely dependent on interindividual variability (Mazur 1998; Morley 2001). It 
is noteworthy that basal and dynamic peak cavernosal velocity at Penile Doppler 
Ultrasonography (PDU) examination is reduced in older patients (Corona et al 
2004), and the pathophysiology of erectile dysfunction in this patient group mainly 
includes chronic ischemia, which triggers the deterioration of cavernous smooth 
muscle and the development of corporeal fibrosis. Generally, ED is associated with 
illnesses with a common basis of endothelial dysfunction, like diabetes mellitus, 
heart disease, and hypertension, whose prevalence increases with age (Virag 
et al 1985; Feldman et al 1994; Aversa et al 2002). The neural and endothelium-
dependent mechanisms that would normally cause relaxation in corporal smooth 
muscle are impaired in tissue collected from men with diabetes and ED (Saenz 
De Tejada et al 1989). This body of knowledge leads to the assumption that 
ED is mainly a neurovascular disease (Virag et al 1985; Sullivan et al 2001), and 
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is strongly supported by the evidence that speciﬁ  c PDE5 
inhibition enhances vasodilatation in the corpus cavernosum 
(Ballard et al 1998) producing an efﬁ  cient erection in a 
wide range of ages and conditions (Frajese and Pozzi 2003). 
Since the introduction of sildenaﬁ  l, remarkable progress 
has been made in the treatment of erectile dysfunction. At 
present, inhibition of PDE5 with oral agents appears to be 
the treatment of choice (Kubin et al 2003). The critical role 
of PDE5 in penile erection and the availability of the new 
speciﬁ  c and potent inhibitors, tadalaﬁ  l and vardenaﬁ  l, have 
enabled the development of effective treatment strategies. 
PDE5 inhibitors are a safe and efﬁ  cacious option for most 
elderly patients, and now represent ﬁ  rst-line therapy also 
for their socio-economic impact (Anastasiadis et al 2002). 
An efﬁ  cacious erectogenic effect by drugs is deﬁ  ned as 
an erection adequate for vaginal penetration and leading 
to successful intercourse. Nevertheless, considering the 
frequent association of sexual and medical problems in 
the aged, a holistic approach toward the treatment of 
ED should include counseling, adjustment of lifestyle, 
and modiﬁ  cation of risk factors, such as medication, 
overweight, smoking, alcohol consumption, and lack of 
exercise (Meuleman 2002). 
Due to its peculiar chemical and pharmacokinetics 
properties (essentially half-life), tadalaﬁ  l may be considered 
as the least “typical” among the current generation of 
PDE5 inhibitors (Montorsi et al 2004). Providing more 
ﬂ  exibility in dosing and more continuity in pharmacological 
action, tadalaﬁ  l may ameliorate both sexual behavior and 
physiological processes leading to penile erection. This can 
be reﬂ  ected on both efﬁ  cacy and safety issues of the therapy 
of ED, in short as well as in long-term treatment. While the 
discovery of sildenaﬁ  l opened a new era, mainly defeating 
the “impotence” of physicians in treating ED, the availability 
of tadalaﬁ  l seems to give new perspectives as far as the 
treatment strategy and cure of ED is concerned.
A clinical pharmacological 
approach to the effective and safe 
use of tadalaﬁ  l
The mechanism of action leading to penile erection 
involves inhibition of PDE5, the major cyclic guanosine 
monophospate (cGMP) hydrolyzing enzyme located in the 
vascular smooth muscle cells of corpus cavernosum. Sexual 
stimulation triggers the release of the endothelium dependent 
relaxing factor nitric oxide (NO) (Saenz De Tejada 1989), 
stimulating through the protein kinase G the release of 
guanylyl cyclase with an increase of intracellular cGMP, 
thus causing a decrease in intracellular calcium and, 
ultimately, the relaxation of trabecular erectile tissues and 
the dilatation of the helicine artery of the penis (Burnett et al 
1992). The increase in blood ﬂ  ow causes the engorgement 
of the sinusoidal spaces of the corpora cavernosa, the tunica 
albuginea compresses the subtunical venules that drain 
the corpora and reduces the venous outflow increasing 
penile blood pressure and causing erection (NIH 1992). 
This mechanism acts primarily to maintain the tumescence 
phase, whereas neuronal-derived NO is mainly active in 
the induction of erectile function (Moreland et al 2001). 
Inhibiting PDE5 prolongs the effects of nerve stimulation. 
Tadalaﬁ  l, like the PDE5 inhibitors sildenaﬁ  l and vardenaﬁ  l, 
competitively blocks the cGMP hydrolysis by PDE5, 
thereby fostering cGMP accumulation and the relaxation of 
vascular smooth muscle. Increased concentrations of cGMP 
produce higher PDE5 promoter activities (Lin et al 2002). 
cGMP accumulation stimulates cGMP degradation, but 
the pharmacological PDE5 inhibition blocks this negative 
feedback process. Thus, with PDE5 inhibitors, erection 
develops in a physiologic manner and only with sexual 
stimulation. 
Chronic PDE inhibition, via the persistent activation 
of PDE5 promoters, may up-regulate PDE expression 
and, therefore, be associated with the development of drug 
tachyphylaxis (Moreland et al 1999). It has been shown 
that in the trabecular smooth muscle of the rat penis, 
sildenaﬁ  l moderately down-regulated PDE5 (Ferrini et al 
2004). The clinical long–term consequences of chronic 
PDE5 inhibition are still unknown. It has been reported that 
20% of long-term sildenaﬁ  l responders required increased 
dosages, while 17% discontinued because of loss of efﬁ  cacy 
(El Galley et al 2001). It is also possible that the positive 
erectile response obtained with chronic administration may 
be related to functional tissue modiﬁ  cations involving up-
regulation of either muscarinic receptors, or the transduction 
mechanism leading to the activation of endothelial NO 
synthase (Behr Roussel et al 2004). As PDEs are expressed 
in different tissues, selectivity is a prerequisite for therapeutic 
application of PDE inhibitors. Tadalaﬁ  l is selective for PDE5 
and minimally inhibits PDE6 (Angulo et al 2001), which 
works for visual transduction in the retina. With respect 
to PDE5, a 780-fold greater concentration of tadalaﬁ  l is 
needed to inhibit PDE6, and a 14-fold greater concentration 
to inhibit PDE11, an enzyme with unknown physiological 
function. Tadalaﬁ  l’s nonselectivity with respect to PDE1 
(expressed in the brain, myocardium, and vascular smooth Clinical Interventions in Aging 2006:1(4) 441
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muscle cells), may result in vasodilatation and tachycardia 
(Bischoff 2004).
Tadalaﬁ  l is rapidly absorbed with the maximum plasma 
concentration occurring at 2.0 h, the extended terminal 
half life being 17.5 h (Patterson et al 2001; Rosen et al 
2001). The rate and extent of absorption of tadalaﬁ  l is not 
altered by food ingestion, age, diabetes, or mild to moderate 
hepatic insufﬁ  ciency (Patterson et al 2001). The earliest 
signiﬁ  cant time from dosing to erectogenic effect, objectively 
determined by a stopwatch in a placebo-controlled design, 
is 16 minutes with tadalaﬁ  l 20 mg, and 30 minutes with 
the dose of 10 mg (Rosen et al 2004). This demonstrates 
that effective plasma level is achieved before reaching 
the maximum plasma concentration. Nevertheless, most 
men would require more time for tadalaﬁ  l to be optimally 
effective; in particular, patients with severe ED or older 
patients should be encouraged to optimize the period of 
sexual stimulation. 
In healthy subjects, over a range of 2.5–20 mg, tadalaﬁ  l’s 
systemic exposure increases proportionally with the dose. 
Steady state plasma concentrations are attained within 
5 days of once-daily dosing, with an exposure that is 
approximately 1.6-fold greater than after a single dose (Eli 
Lilly 2006).
The clinical evidence: efﬁ  cacy of 
tadalaﬁ  l in ED
The most important outcome for an ED therapy is the 
patient’s perception of success (Hanson-Divers et al 1998). 
When patients with ED experience a successful intercourse 
after treatment, they feel cured of their problem. Furthermore, 
they express the desire of unplanned, unpremeditated or 
spontaneous sexual intercourse. In this sense, one possible 
use of the self-administered questionnaire International Index 
of Erectile Function – Erectile Function domain (IIEF-EF) 
score is to ascertain whether patients return to normal erectile 
function after treatment, with scores of 26–30 representing 
the normal ranges (Rosen et al 1999; Mulhall 2003). 
Integrated analysis of data from phase III trials demonstrated 
that tadalaﬁ  l, at doses from 5 mg to 20 mg versus placebo, 
signiﬁ  cantly improved erectile function (EF) by all measures. 
In particular, 50%–65% of patients, regardless of ED severity 
at baseline, returned to normal erectile function with almost 
60%–90% of success rate at intercourse attempts during 
active treatment. 
In the community-based Massachusetts Male Aging 
Study (MMAS) (Feldman et al 1994), 52% of 1290 men 
aged 40 to 70 years were found to have some degree of  ED. 
The probability was 9.6% in the whole sample, and higher 
in men aged 60–69 years (40%) and in those treated for 
heart diseases (39%), diabetes (28%), or hypertension 
(15%). This indicates that ED is often a symptom present 
in cardiovascular disease and diabetes. Analogously, in the 
majority of the studies reported in this review the population 
selected is similar, as far as age and causes of ED are 
concerned, to that of MMAS. 
With the purpose of assessing efﬁ  cacy and safety of 
tadalaﬁ  l in the treatment of ED, an integrated analysis of 
ﬁ  ve randomized double-blind placebo controlled parallel 
group trials was conducted (Brock et al 2002). An update of 
this analysis has been made with six newest tadalaﬁ  l studies 
including an additional group of 1215 men with ED (Carson 
et al 2004). The ﬁ  nal analysis included eleven studies with 
2102 patients (mean age 56 years, age range 22–88 years) 
who had a minimum 3-month history of mild (36%), 
moderate (27%), or severe (33%) ED, of organic (58%), 
psychogenic (12%), or mixed etiology (31%). Hypertension, 
diabetes mellitus, and hyperlipidemia were the most common 
comorbidities.
The subjects were randomly allocated to a 12-week 
treatment with placebo (n=638) or tadalaﬁ  l at ﬁ  xed daily 
doses of 2.5 mg (n=74), 5mg (n=151), 10 mg (n=321), 
and 20 mg (n=1143). The doses of 2.5 mg and 5 mg were 
included only in the “ﬁ  ve studies analysis”. Treatment was 
self administered as needed before sexual intercourse with 
no restrictions on food or alcohol intake or timing of sexual 
activity. Exclusion criteria were impotence due to radical 
prostatectomy, pelvic surgery, penile deformities, or recent 
history of stroke or spinal cord trauma, severe cardiovascular 
diseases and/or clinically significant renal or hepatic 
insufﬁ  ciency. Men treated with nitrates, antiandrogens or 
cancer chemotherapy agents were also excluded from study 
participation. The international index of erectile function 
(IIEF) (Rosen et al 1999), that includes the domains of EF, 
intercourse satisfaction, orgasmic function, sexual desire 
and overall satisfaction, was used to globally evaluate EF. 
In particular, ED severity in the EF domain is scored mild 
(22–25), moderate (11–21), and severe (≤10) (Cappelleri 
et al 1999). The diary Sexual Encountered Proﬁ  le (SEP) that 
consists of 6 and 4 yes/no questions to be answered by the 
patient and the partner respectively, and Global Assessment 
Question (GAQ) related to improvement of erections and 
ability to engage in sexual activity, were also administered 
at baseline and following treatment to evaluate the effect 
of therapy on successful completion of intercourse and 
satisfaction. Compared with placebo, tadalaﬁ  l signiﬁ  cantly Clinical Interventions in Aging 2006:1(4) 442
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enhanced, in a dose-dependent manner, in patients of 
different ages, all efﬁ  cacy outcomes across disease etiologies 
and severities. The primary efﬁ  cacy outcome measure was 
the EF domain that consists of 6 questions with possible 
score range from 1 (worse function) to 30 (normal function). 
The score increase was <0.1 for placebo, and respectively 
3.2, 4.6, 6.5, and 8.6 for tadalaﬁ  l 2.5 mg, 5 mg, 10 mg, and 
20 mg (p<0.05–0.001 vs placebo). Two other co-primary 
efﬁ  cacy variables were the mean changes from baseline to 
end-point on the ability in penetration and length of erection 
for a successful intercourse, measured by questions 2 (“were 
you able to insert your penis into your partner’s vagina?”) 
and 3 (“did your erection last long enough for you to have 
successful intercourse?”) of the SEP diary. The change 
of positive response to the questions 1 and 2 signiﬁ  cantly 
increased from 2.3% and 8% for placebo, to 15% and 20%, 
16% and 22%, 24% and 34%, 30% and 46% respectively, 
for tadalaﬁ  l 2.5 mg, 5 mg, 10 mg, and 20 mg (p<0.001 vs 
placebo). Across all patients on tadalaﬁ  l 10 mg and 20 mg, 
71% and 84% reported improved erection (GAQ) versus 33% 
in the placebo group. The total number of successful attempts, 
as a proportion of the total number of attempts made, was 
61% and 72% respectively, compared with 34% of placebo 
(p<0.001). Both 20 mg and 10 mg doses were signiﬁ  cantly 
better than placebo in improving patients’ EF. Based on 
the cause of ED, there was a similar trend in the IIEF–EF 
domain score improvements, with the 20 mg group that had 
numerically greater mean changes across all severity groups 
than the 10 mg group. The greatest percentage of tadalaﬁ  l 
treated patients having normal EF at end-point were those 
with mild baseline ED, followed by those with moderate 
and severe ED. 
To evaluate the efficacy of tadalafil in men with 
ED by demographic and ED characteristics, Lewis and 
colleagues (2005) extended post-hoc the analysis of 
the “eleven double-blind trials” (Carson et al 2004). In 
particular, etiology, severity, duration, presence of comorbid 
conditions such as obesity, diabetes mellitus, hypertension, 
cardiovascular disease, hyperlipidemia, depression, benign 
prostatic hyperplasia (BPH), or concomitant treatment 
with antihypertensive or antidepressant drugs have been 
considered. Younger patients (<65 years) had numerically 
better scores than older patients on each of the efﬁ  cacy 
measures, although the differences were small after 
accounting for the slightly better baseline characteristics in 
younger patients. When age was considered, the percentage 
of patients attaining normal EF at end-point (IIEF–EF 
domain ≥26) was significantly superior in the younger 
treatment groups (p<0.001). Overall, tadalafil proved 
to be effective in improving erectile function across a 
variety of patient demographics and illness characteristics 
including ED etiology, duration, severity, comorbidity, and 
concomitant treatments. Obesity is generally associated 
with increased risk of medical conditions such as diabetes 
mellitus, hypertension, depression or cardiovascular 
diseases, and BPH. This was reﬂ  ected in these ED studies 
with 66% of obese patients (Body Mass Index [BMI] >30) 
affected from these concomitant illnesses in comparison to 
the BMI <30 subjects that were affected by 53% (p<0.001). 
The obese subgroup had a statistically nonsigniﬁ  cant lower 
score on each of the efﬁ  cacy measures with respect to the 
rest of the sample. The group of patients with organic ED 
etiology had lower baseline scores on both IIEF–EF and 
SEP-Q3 and accounts for the 67% of severe ED compared 
with the mixed (25%) and psychogenic subgroups (8%). 
As already expected (Emmick et al 2002; Saenz De 
Tejada et al 2002), whether affected from diabetes or 
hypertension, these subgroups had lower baseline and 
end-point scores. Both tadalaﬁ  l doses showed statistically 
greater improvement than placebo for each ED severity 
level, with more pronounced amelioration in the moderate 
and severe ED patients because of the lower baseline scores. 
The subgroups of patients with comorbid conditions taking 
tadalaﬁ  l 20 mg showed signiﬁ  cant improvements from 
baseline to end-point.
Early treatment success may be important in enhancing 
self-confidence to continue successful treatment. An 
integrated post-hoc analysis of the “ﬁ  ve double-blind 
studies” (Brock et al 2002) examined the ﬁ  rst dose success, 
the cumulative success by dose and the maintenance of 
success among men taking tadalaﬁ  l (Shulman et al 2004). 
The SEP diary questions assessed these three perspectives. 
With the ﬁ  rst dose, signiﬁ  cantly greater proportions of 
men taking tadalafil 10 mg and 20 mg versus placebo 
achieved successful erection (SEP-Q1: 85% and 90% vs 
66% respectively), successful penetration (SEP-Q2: 74% 
and 79% vs 47% respectively), successful intercourse 
(SEP-Q3: 56% and 67% vs 31 % respectively), and were 
satisﬁ  ed overall with their sexual experience (SEP-Q5: 36% 
and 47% vs 15%, respectively; all p<0.001). Regardless of 
the ED severity or patient age, continued dosing increased 
the proportion of men achieving ﬁ  rst success, reaching 
a plateau between dose 4th and 8th at approximately 
95% (SEP-Q2), 90% (SEP-Q3), and 81% (SEP-Q5). 
After ﬁ  rst-dose success, success rate in a 12-week period 
was signiﬁ  cantly greater for men taking tadalaﬁ  l versus Clinical Interventions in Aging 2006:1(4) 443
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placebo (SEP-Q2: 85% and 91% vs 75%; SEP-Q3: 81 
and 88% vs 64%, respectively; p<0.001). Note the high 
proportion of patients attaining initially a successful 
erection while on placebo. This success was not maintained 
under the measures of successful penetration, intercourse, 
and satisfaction.
In a large population of men from Central and 
Eastern Europe and Eastern Mediterranean (mean age 
52 years; range 21–82 years), after 12 weeks of on 
demand treatment, tadalafil 20 mg versus placebo has 
confirmed its superior efficacy, also after stratification 
of IIEF–EF severity class from mild and moderate to 
severe (Skoumal et al 2004). Tadalafil patients achieved 
a normal IIEF–EF score at endpoint, compared with 16% 
of placebo patients (p<0.001), and compared with placebo, 
have a significantly higher end-point and a greater change 
from baseline across all domains of IIEF. The same 
conclusions on tadalafil 20 mg were yielded in similar 
trials with populations of different ethnicity (Allen et al 
2004; Carson et al 2005). In particular, in a multicentric 
trial conducted both in Italy and UK (Eardley et al 2004), 
involving nearly 41% of severe ED patients (mean age 53; 
range 26–78 years), tadalafil 20 mg on-demand improved 
mean EF domain scores by 11.1, versus 0.4 of placebo 
(p<0.001), with 74% of successful intercourse attempts 
compared with 30% of placebo. This is the largest 
numerical improvement observed in the IIEF–EF domain 
with tadalafil. Tadalafil significantly improved IIEF 
satisfaction domain and GAQ overall effect on erection 
(82% vs 23%) and sexual activity (79% vs 17%). These 
results mirror those observed in the “five studies analysis” 
(Brock et al 2002).
Regardless of the degree of ED, tadalaﬁ  l 20 mg every 
other day for one month has been shown to improve 
endothelial function in patients with increased cardiovascular 
risk (Rosano et al 2004), since endothelial damage is a 
common marker of diseases of the cardiovascular system. 
The beneﬁ  t was sustained two weeks after treatment 
discontinuation and was associated with an increase in 
nitrite/nitrate levels and a decrease in endothelin-1. Age 
itself is an important risk factor for vascular disease and 
ED, and thereby endothelial dysfunction. In elderly patients 
(60–70 years) affected by ED, with slight or no signs of 
carotid disease, resumption of spontaneous erections was 
obtained with chronic tadalaﬁ  l 20 mg administered for 
three months on alternate days. One month after withdrawal 
from dosing, spontaneous improvement in sexual function 
was reported in 55%–65% of patients unaffected from 
carotid disease and in 16% of those with increase of carotid 
intimal thickness (Caretta et al 2005). Nocturnal penile 
tumescence rigidity monitoring and PDU parameters 
were inversely related to different degrees of carotid wall 
alteration and showed a signiﬁ  cant improvement in those 
patients with atherosclerotic plaques, probably due to the 
amelioration of endothelial function during treatment.
A retrospective analysis of pooled data from 12 
placebo-controlled trials was conducted to characterize 
the efﬁ  cacy and safety of tadalaﬁ  l in men with diabetes 
mellitus (Fonseca et al 2004). Baseline characteristics of 
ED severity, assessed by IIEF–EF, scored 12.6 in diabetics 
and 15 in nondiabetics (p<0.001). These scores correlated 
inversely with glycosylated hemoglobin (HbA1c) levels. 
Regardless of glycemic control and diabetic therapy, 
tadalafil 10 mg and 20 mg, compared with placebo, 
improved all primary efﬁ  cacy outcomes in all patients. 
The subgroup receiving tadalaﬁ  l 20 mg experienced a mean 
improvement of 7.4 in the IIEF–EF domain score from 
baseline versus 0.9 for placebo (p<0.001), reporting a 53% 
average of successful intercourse attempts, compared with 
22% for placebo. 
Tadalafil 20 mg was effectively administered in the 
treatment of 303 men suffering from ED following bilateral 
nerve sparing radical retropubic prostatectomy (Montorsi, 
Padma-Nathan, et al 2004). Compared with placebo, a 
greater improvement on all the evaluated end-points was 
reported. IIEF–EF domain score increased by 5.3 (p<0.001 
vs placebo), and positive response for SEP-Q2 and Q3 was 
for 54% and 41% of patients. A subgroup of patients with at 
least a post-operative tumescence, meaning a post-surgical 
minimal cavernous innervation damage, reported an increase 
of 5.9 points on the IIEF–EF and of 69% and 52% on SEP-
Q2 and Q3.
In a randomized blind cross-over trial for the treatment 
of ED in 30 male spinal cord-injured patients (mean 
age 34.6, range 21–60 years) tadalaﬁ  l 10 mg was compared 
with sildenaﬁ  l 50 mg (Del Popolo et al 2004). In these 
patients, either psychogenic erections or reﬂ  exive spinally 
elicited erections or both are necessary for PDE5 inhibitor 
response. Tadalafil and sildenafil allowed patients to 
achieve erections whit a mean total score on IIEF of 17.82 
and 15.75 (increase from baseline of 58.41% and 40%) 
respectively. No signiﬁ  cant differences were observed 
up to 12 h, while, as expected, normal sexual functioning 
and improved overall sex satisfaction up to 24 h post-
dosing was better for tadalaﬁ  l compared with sildenaﬁ  l 
(p<0.01).Clinical Interventions in Aging 2006:1(4) 444
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The clinical evidence: safety of 
tadalaﬁ  l in ED
Most of the side effects reported in the clinical trials are 
dose-dependent and consistent with the vasodilatatory 
effect of PDE-5 inhibition. When tadalaﬁ  l was administered 
on an on-demand basis headache and dyspepsia were the 
most frequent symptoms, followed by back pain, nasal 
congestion, myalgia, and ﬂ  ushing. Subgroup analyses have 
revealed no differences between incidences of adverse events 
in tadalaﬁ  l-treated men over 65 years compared with the 
younger group. No relevant differences in the frequency and 
pattern of side-effects have been reported when tadalaﬁ  l was 
schedully administered (eg, three times per week, or daily). 
The daily administration of tadalaﬁ  l was well tolerated with 
headache, dyspepsia, facial ﬂ  ushing, nasal congestion, and 
backache as the most frequently reported adverse events 
(McMahon 2004). In the “eleven trials analysis” (Carson 
et al 2004), adverse events leading to study discontinuation 
account for 3.2% of patients taking tadalaﬁ  l 20 mg, 1.6% 
of patients taking tadalaﬁ  l 10 mg and 1.3% of patients on 
placebo. Respectively, 51%, 58%, and 39% of the subjects 
experienced at least one or more unwanted symptoms. Side-
effects were generally mild to moderate and decreased in 
frequency during continued treatment. While no signiﬁ  cant 
laboratory or electrocardiographic changes were assessed, 
the most common treatment-emergent adverse events 
were headache (15%, 12%, 5% respectively), dyspepsia 
(8%, 7%, 1% respectively), back pain/myalgia (8%, 11%, 
3% respectively), nasopharyngitis and nasal congestion 
(4%, 11%, 5% respectively), flushing (3%, 3%, 1% 
respectively), pain in limb (3%, 3%, 1% respectively). 
In a comprehensive review on the cardiovascular effects 
of tadalaﬁ  l, a safety assessment of more than 4000 subjects 
who received the drug during clinical studies was performed 
(Kloner et al 2003). When tadalaﬁ  l 10 mg and 20 mg was 
administered to healthy subjects, minimal, but statistically 
signiﬁ  cant differences over placebo in standing systolic 
(SBP) and diastolic blood pressure (DBP) were observed. 
Tadalaﬁ  l 20mg administered daily for 26 weeks in healthy 
volunteers or in subjects with mild ED (age ≥45 years) did 
not result in signiﬁ  cant changes in sitting SBP or DBP. 
A small decrease in standing SBP and DBP has been reported 
in patients with chronic stable angina treated with different 
doses of tadalaﬁ  l (5 mg and 10 mg), however, these changes 
were greater and statistically signiﬁ  cant with respect to 
placebo in the so called “outlier patients”, in whom a decrease 
of >30 mm Hg in SBP or >20 mm Hg in DBP from baseline 
was recorded.
An update on thirty-ﬁ  ve placebo-controlled and eight 
open clinical trials of tadalaﬁ  l demonstrated no increased 
risk of cardiovascular adverse events such as myocardial 
infarction, cerebrovascular events or cardiac mortality 
(Jackson et al 2004). 
The evidence that duration of action for tadalaﬁ  l is 
well beyond the elimination half-life, advises for a careful 
monitoring of its long-term effect. However, the duration 
of side-effects has not been measured in the majority of 
the studies. Due to the potential for a clinically signiﬁ  cant 
decrease in blood pressure, the major contraindications 
of the PDE5 inhibitors are concomitant use with nitrates 
or molsidomine-containing medications, because of the 
increased sensitivity to nitroglycerin (Dishy et al 2001). 
Interaction between grapefruit juice and sildenaﬁ  l, tadalaﬁ  l, 
or vardenaﬁ  l may cause serious systemic vasodilatation 
(Bailey and Dresser 2004), and we do suggest such a 
possibility with alcohol as well (Frajese and Pozzi 2005). 
Since men with ED have high incidence of cardiovascular 
disease, diabetes mellitus and BPH, they are likely to 
be taking medications that affect blood pressure like the 
alpha-blockers terazosin and doxazosin (Simonsen 2002). 
Tadalaﬁ  l augmented the hypotensive effects of doxazosin, 
but had little hemodynamic interaction with tamsulosin, a 
drug prescribed for BPH (Kloner et al 2004). The long-term 
safety and tolerability of tadalaﬁ  l 10–20 mg in the treatment 
of erectile dysfunction has been assessed, evaluating in a 
18–24 month open extension trial in 1173 subjects (mean 
age 57, range 23–83 years) (Montorsi, Verheyden, et al 
2004). Notably, 74% of patients were taking concomitant 
medication for comorbid conditions, including diabetes 
mellitus (30.5%) and hypertension (29.5%). After three 
months, 72% of patients had chosen the 20mg dose. 173 
(14.7%) of men discontinued because of perceived lack 
of efﬁ  cacy over 18–24 months of treatment. 234 (20%) 
and 493 subjects (42%) completed 18 and 24 months 
of treatment respectively. The total tadalafil exposure 
was 1676 patient-years. Headache (15.8%), dyspepsia 
(11.8%), nasopharyngitis (11.4%) and back pain (8.2%) 
were the most common treatment emergent side-effects. 
Consistent with the low afﬁ  nity of tadalaﬁ  l for PDE6, only 
1 patient complained of cyanopsia (blue vision). The rate 
of discontinuation due to adverse events was 6.3%. No 
clinically signiﬁ  cant laboratory, or electrocardiographic 
ﬁ  ndings, or changes in vital signs, or serious adverse events 
(8.6%), or major safety concerns were causally associated 
with tadalaﬁ  l administration. Clinical Interventions in Aging 2006:1(4) 445
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Back pain or myalgia or both appearing as a consequence 
of PDE5 inhibition was experienced by 8.3%–9.4% of 
men taking tadalaﬁ  l 10–20 mg. The potential mechanism 
of this side effect remains unknown. The underlying 
symptoms include diffuse bilateral lower lumbar gluteal, 
thigh, or thoracolumbar muscular discomfort, exacerbated 
by recumbency. The integrated analysis of ten placebo-
controlled tadalaﬁ  l studies, including 1846 patients (Seftel 
et al 2005), showed that laboratory markers of inﬂ  ammation 
or muscle damage and renal plasma ﬂ  ow were unchanged 
with respect to baseline, and no lumbar or gluteal myositis 
was evidenced by positron emission tomography scan or 
magnetic resonance imaging. 
Across tadalaﬁ  l clinical trials no impairment of blue-
green color discrimination was detected, and color vision 
alterations were rare (0.1%) (Eli Lilly 2006). Chronic 
tadalaﬁ  l administration has no detrimental effect on human 
spermatogenesis or reproductive hormones (Ellstrom et al 
2003). 
Treatment strategies and effect on 
sexual behavior
Although efficacy and safety are two important 
characteristics when choosing a pharmacological treatment 
for ED, the ideal therapy should be reliable during 
maintenance. Furthermore, beyond erection and penetration, 
intercourse success and overall satisfaction needs have to 
be considered. The primary goal in the treatment of ED 
should be the restoration of sexual life rather than merely 
the achievement of a penile erection. 
An important characteristic of tadalaﬁ  l is its prolonged 
period of responsiveness. In prescribing a therapy for ED, 
the long lasting effect of the drug may not be the most 
important issue. Tadalaﬁ  l is unique to the PDE5 inhibitors 
available because of its efﬁ  cacy up to 36 h after dosing. This 
should release from the need to plan sexual activities and 
therefore favor spontaneity. 
In a study designed to assess whether tadalaﬁ  l 20 mg 
was associated with a treatment effect discriminated from 
placebo (Porst et al 2003), a greater proportion of successful 
intercourse attempts up to 36 hours post-tadalafil dose 
compared with placebo at 24 h and 36 h was reported. Fifty-
three percent versus 29% (p<0.001) of successful intercourse 
attempts according to SEP-Q3 was undertaken up to 24 h, and 
59% versus 28% (p<0.001) within 36 h after dosing. 
In a randomized prospective placebo-controlled trial, 
the chronological distribution of sexual intercourse was 
evaluated (De Rose et al 2005). Tadalaﬁ  l 20 mg administered 
twice a week resulted in a signiﬁ  cant change of sexual 
attitude with the highest percentages of successful 
intercourse after 6–12 h (35%), and 12–24 h (28%) 
from dosing. It should be mentioned that 5% and 2% of 
intercourse were recorded up to 48 h and 60 h, while none 
of the placebo patients has reported sexual intercourse 
over 16 h. Recovery of spontaneous night, awakening, and 
day long erections at the rate of 78% was also reported. 
Besides the quality of sexual intercourse, these results 
showed an improvement of sexuality in the broadest sense. 
Unfortunately, due to the low mean age of patients enrolled 
(46 years), it is difﬁ  cult to extrapolate this data to elderly 
patients.
When taken on demand, tadalaﬁ  l 20 mg versus placebo 
allows a range of 62%–74% (vs 0%–33%) of successful 
intercourse attempt rate up to 36 h (p<0.001 up to 24 h; 
p=0.017 up to 36 h) (Allen et al 2004; Seftel et al 2005). 
Patients on tadalafil changed their sexual behavior 
signiﬁ  cantly when on an alternate dose regimen (3 times/
week) and had sexual attempts distributed over a wide 
period of time post dosing (Mirone et al. 2005). The on-
demand regimen versus scheduled use was evaluated in 
4262 patients in a cross-over open-label study conducted to 
assess patient’s choice of treatment regimens. Overall, both 
regimen were effectives with a normal IIEF–EF domain 
score (≥26) achieved by 60.2% and 62.3% of patients, and 
a 72.6% and 74.4% mean per patient intercourse success 
rate. A preference for the on-demand administration was 
expressed by 57.8% of patients. An analysis of preferences 
based on comorbidities associated with ED (Moncada et al 
2005) showed that the on demand regimen was preferred in 
each subgroup except for the depressed patients, in which 
53% expressed preference for the 3 times/week treatment. 
It was concluded that the patient’s choice of treatment 
regimens is not exclusively determined by demographics 
or clinical features, but is possibly related to individual 
cultural and psychosocial factors. Forty seven percent of 
the attempts on the on-demand regimen and 71% on the 
3 times/week treatment were performed by patients more 
than 4h post-dosing. The efﬁ  cacy of tadalaﬁ  l 20 mg was 
more than 70% (mean-per-patient) success rate regardless 
of the time interval post-dosing. Since age is a potential 
inﬂ  uencing factor on sexual habits, a subgroup analysis of 
age was performed. On three cohorts of patients aged <40, 
40–65, and >65 years, overall 52%–56% of attempts were 
performed within 4h post-dosing with on-demand regimen 
and 68%–71% of attempts beyond 4h post-dosing with the 
3 times/week interval. In all the three groups the evening Clinical Interventions in Aging 2006:1(4) 446
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was the preferred time for sexual activity, but with increasing 
age fewer weekend attempts (about 51%, 48%, and 45% 
respectively) and more morning attempts were observed on 
the 3 times/week regimen (about 13%, 22% and 28% for 
patients aged >65 years). Moncada and collegues (2005) 
commented that this behavior may be a general response 
to a less pronounced perception of a deadline to engage in 
sexual activity and to the major availability of time for sexual 
activity in the older patients and their partners. 
Similar results emerged from the post-hoc analyses 
(Shabsigh et al 2005) assessing the time from dosing to 
sexual intercourse attempts of the “eleven double-blind trials” 
(Carson et al 2004) and of the double-blind studies conducted 
in eastern Europe (Hatzichristou et al 2005). Regardless 
of age, ED severity or previous experience with sildenaﬁ  l, 
most patients attempted sexual intercourse 12–36 h after 
one dose of tadalaﬁ  l and did not adhere to a ﬁ  xed schedule 
of intimacy. 
In several clinical studies for the treatment of ED, a 
signiﬁ  cant greater efﬁ  cacy of PDE5 inhibitors in the younger 
with respect to older subjects (89.1% vs 65.7%; p<0.01) 
has been reported (Tsujimura et al 2002). The progression 
of endothelium dysfunction and of penile vascular disease, 
androgen deﬁ  ciency, reduced sexual desire and appealing, 
and psychogenic issues are often the reason for a low 
response to PDE-5 inhibition (McMahon 2004). 
It was shown that while serum T and prolactin (PRL) 
were similar between young and elderly groups, mean serum 
luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) concentrations signiﬁ  cantly differed below and over 
65 years (5.2 and 8.7 mIU/mL vs 11.0 and 18.9 mIU/mL, 
respectively; p<0.01). This may be partly explained by 
the increasing number of pathologies observed with aging 
(Eisenhardt and Siffert 2003), although a signiﬁ  cant role is 
played by the decline in gonadal (Mazur 1998; Aversa et al 
2000; Derby et al 2001; Harman et al 2001) as well as in 
hypothalamic–pituitary functions (Pincus et al 1997). Older 
males secrete LH and T more irregularly, and jointly more 
asynchronously than younger males (Pincus et al 1996), 
although hormone levels fell in the normal range. On the 
other hand, androgens may inﬂ  uence sexual behavior by 
acting within the central nervous system, and through 
regulatory effects on several neurotransmitter systems, in 
particular dopamine and serotonin (Steers 2000). In the same 
way, both sexual desire and erectile function are responsive 
to testosterone and lack of sexual activity decreases T levels 
(Ahn et al 2002). There is a T threshold below which libido 
and sexual function are impaired, but no evidence of a 
correlation between ideational or erectile components of 
sexual function and T level in the normal range of circulating 
androgens has been reported before (see Rubinow and 
Schmidt 1996).
In a trial comparing sildenaﬁ  l and tadalaﬁ  l (Carosa et al 
2004) in the treatment of ED, basal T and FT levels in the 
lower normal range, and LH level at the top of the normal 
range, were reversed during treatment. An LH reduction 
and a testosterone rise, well within the normal laboratory 
values, were observed. The T and FT increase in sildenaﬁ  l 
patients was signiﬁ  cantly lower than in those treated with 
tadalaﬁ  l (4.7 ± 2.7 vs 5.1 ± 0.9, p<0.001). The full sexual 
intercourse frequency also signiﬁ  cantly roused to a 4.9 ± 
2.9/month intercourse rate for sildenaﬁ  l and 6.9 ± 4.6/month 
(p=0.04) for tadalaﬁ  l, because the longer half-life of the 
latter facilitates the higher frequency of intercourse, as was 
concluded by the study. Whether the observed changes in 
the hormonal pattern may be attributed to the increased 
sexual activity, or directly due to the PDE5 inhibition 
(eg, NO stimulates hypothalamic gonadotropin-releasing 
hormone [Kohsaka et al 1999], and inhibits PRL release 
in rats [Velardez et al 2000]) remains to be determined. 
However, no signiﬁ  cant correlation between frequency of 
sexual intercourse and T level has been found by Goldstein 
and colleagues (1998) in aged ED patients. 
The efﬁ  cacy of PDE5 inhibitors is probably related to 
the extent and severity of ED. In patients suffering from 
ED with diabetes, or severe vasculogenic disease, or post-
radical prostatectomy, a significantly reduced efficacy 
of these drugs was demonstrated in several experiences 
(Goldstein et al 1998; Emmick et al 2002; Saenz De Tejada 
et al 2002). Different salvage strategies have been applied 
in such cases (McMahon 2002; Atiemo et al 2003). In a 
clinical trial (McMahon 2004) involving subjects with ED 
of predominantly vasculogenic etiology, (mean age of 63; 
range 21–79 years), previously unresponsive to on-demand 
tadalaﬁ  l, daily administration of tadalaﬁ  l, at the ﬂ  exible dose 
of 10–20 mg signiﬁ  cantly enhanced all efﬁ  cacy outcome 
variables. Improved erections at end-point were reported by 
69% of men compared with 42% of men with on-demand 
tadalaﬁ  l. A signiﬁ  cant improvement in the IIEF–EF domain 
of 12.8 versus pre-treatment (p<0.001), and of 8.2 from on-
demand tadalaﬁ  l baseline (p<0.001) was reported. Sexual 
intercourse was successfully completed on 58% of attempts 
with daily tadalaﬁ  l 10 mg compared with 21% at baseline, 
and 28% with on-demand tadalafil 20 mg (p<0.001). 
However, McMahon (2004) hypothesized that although the 
potential for tachyphylaxis (Moreland et al 1999) is probably Clinical Interventions in Aging 2006:1(4) 447
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low for on-demand use of PDE5 inhibitors, the long lasting 
duration of tadalaﬁ  l’s effect and its chronic use may facilitate 
the loss of treatment efﬁ  cacy.
Conclusions
With an effectiveness that lasts up to 36 h, tadalaﬁ  l could 
provide nearly continuous coverage when taken on a 
regular basis, allowing patients and their partners to choose 
freely when to have sexual activities without the need of 
timing it. This property of tadalaﬁ  l explains why patients 
suffering from ED showed positive feedback in terms of 
quality of life related to the treatment. Although various 
studies reported the superior pharmacokinetic properties 
of tadalaﬁ  l compared with the other PDE5 inhibitors, this 
should be cautiously interpreted, especially in the elderly, 
because up to now it has not been entirely deﬁ  ned the 
impact that such a long lasting effect could have both on 
clinical effectiveness and safety, especially in the presence 
of comorbid conditions or other drugs. Nevertheless, the 
efﬁ  cacy of tadalaﬁ  l was demonstrated in patients of all 
ages across disease severities and etiologies with a broad 
range of outcomes, including improved erections, hardness, 
ability to penetrate the partner’s vagina, maintenance of 
erection, intercourse satisfaction, and overall satisfaction. 
The treatment choices that are possible with tadalaﬁ  l allow 
patients to take the drug on a regular basis and to regain 
satisfaction with sex life.
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